{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:10:17Z","timestamp":1793581817033,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:31:44Z","timestamp":1749497504000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Activity of aztreonam-avibactam and ceftazidime-avibactam against \u03b2-lactamase-producing enterobacterales Isolates from United States hospitals"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1132","authenticated-orcid":false,"given":"Lalitagauri M","family":"Deshpande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.06.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025247","article-title":"beta-lactams and beta-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jgar.2025.06.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.VMBF-0016-2015","article-title":"Mechanisms of antibiotic resistance","volume":"4","author":"Munita","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2025.06.002_bib0003","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/cc8892","article-title":"Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant gram-negative infections","volume":"14","author":"Bush","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2025.06.002_bib0004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.06.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on beta-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.06.002_bib0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.06.002_bib0007","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in beta-lactam\/beta-lactamase inhibitor combinations for the treatment of gram-negative bacterial infections","volume":"20","author":"Papp-Wallace","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2025.06.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New beta-lactam-beta-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2025.06.002_bib0009","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018","journal-title":"CLSI"},{"key":"10.1016\/j.jgar.2025.06.002_bib0010","series-title":"Performance Standards For Antimicrobial Susceptibility testing: 34th Informational Supplement","year":"2024"},{"key":"10.1016\/j.jgar.2025.06.002_bib0011","unstructured":"Breakpoint tables for interpretation of MIC's and zone diameters version 14.0. EUCAST. 2024. Available at https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_14.0_Breakpoint_Tables.pdf."},{"key":"10.1016\/j.jgar.2025.06.002_bib0012","first-page":"63","article-title":"CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems","author":"Poirel","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.06.002_bib0013","doi-asserted-by":"crossref","first-page":"ofad038","DOI":"10.1093\/ofid\/ofad038","article-title":"Trends of beta-lactamase occurrence among Escherichia coli and Klebsiella pneumoniae in United States hospitals during a 5-year period and activity of antimicrobial agents against isolates stratified by beta-lactamase type","volume":"10","author":"Castanheira","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.002_bib0014","doi-asserted-by":"crossref","first-page":"dlab136","DOI":"10.1093\/jacamr\/dlab136","article-title":"Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime\/avibactam and comparator agents","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.06.002_bib0015","first-page":"63","article-title":"Comparative activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from U.S. Hospitals","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.06.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.002_bib0017","doi-asserted-by":"crossref","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","article-title":"Changing epidemiology of carbapenemases among carbapenem-resistant Enterobacterales from United States hospitals and the activity of Aztreonam-Avibactam against contemporary enterobacterales (2019-2021)","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.06.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic detection of carbapenemase-producing organisms from clinical isolates","volume":"56","author":"Tamma","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2025.06.002_bib0019","article-title":"Carbapenemase screening in an Irish tertiary referral hospital: best practice, or can we do better?","volume":"2","author":"Fahy","year":"2020","journal-title":"Infect Prev Pract"},{"key":"10.1016\/j.jgar.2025.06.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00337-18","article-title":"Escherichia coli sequence type 410 is causing new international high-risk clones","volume":"3","author":"Roer","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2025.06.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01339-23","article-title":"Escherichia coli sequence type 410 with carbapenemases: a paradigm shift within E. coli toward multidrug resistance","volume":"68","author":"Pitout","year":"2024","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:16:26Z","timestamp":1777101386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"alternative-id":["S2213716525001341"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of aztreonam-avibactam and ceftazidime-avibactam against \u03b2-lactamase-producing enterobacterales Isolates from United States hospitals","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}